$5.74
+0.19
(+3.42%)▲
Live
0.7%
Downside
Day's Volatility :3.88%
Upside
3.2%
20.38%
Downside
52 Weeks Volatility :63.47%
Upside
54.12%
Period | 908 Devices Inc. | Sector (Technology) | Index (Russel 2000) |
---|---|---|---|
3 Months | -2.12% | 6.9% | 0.0% |
6 Months | -25.0% | 5.9% | 0.0% |
1 Year | -20.37% | 21.3% | 0.0% |
3 Years | -82.53% | 38.3% | -20.2% |
Market Capitalization | 189.3M |
Book Value | $4.76 |
Earnings Per Share (EPS) | -1.07 |
Wall Street Target Price | 15.33 |
Profit Margin | -68.56% |
Operating Margin TTM | -123.99% |
Return On Assets TTM | -12.9% |
Return On Equity TTM | -20.61% |
Revenue TTM | 50.7M |
Revenue Per Share TTM | 1.57 |
Quarterly Revenue Growth YOY | 5.3% |
Gross Profit TTM | 26.0M |
EBITDA | -39.1M |
Diluted Eps TTM | -1.07 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.12 |
EPS Estimate Next Year | -0.96 |
EPS Estimate Current Quarter | -0.36 |
EPS Estimate Next Quarter | -0.32 |
What analysts predicted
Upside of 167.07%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 22.1M | - |
Net Income | -7.5M | - |
Net Profit Margin | -34.17% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 18.0M | ↓ 18.51% |
Net Income | -15.2M | ↑ 101.75% |
Net Profit Margin | -84.6% | ↓ 50.43% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 26.9M | ↑ 49.64% |
Net Income | -6.9M | ↓ 54.38% |
Net Profit Margin | -25.79% | ↑ 58.81% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 42.2M | ↑ 56.93% |
Net Income | -22.1M | ↑ 218.86% |
Net Profit Margin | -52.4% | ↓ 26.61% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 46.9M | ↑ 11.01% |
Net Income | -31.7M | ↑ 43.53% |
Net Profit Margin | -67.75% | ↓ 15.35% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 50.2M | ↑ 7.21% |
Net Income | -36.4M | ↑ 14.66% |
Net Profit Margin | -72.47% | ↓ 4.72% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 11.6M | ↓ 26.3% |
Net Income | -9.2M | ↑ 72.33% |
Net Profit Margin | -79.4% | ↓ 45.44% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.5M | ↓ 18.52% |
Net Income | -10.9M | ↑ 17.5% |
Net Profit Margin | -114.49% | ↓ 35.09% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.1M | ↑ 27.48% |
Net Income | -9.3M | ↓ 13.96% |
Net Profit Margin | -77.28% | ↑ 37.21% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 14.3M | ↑ 18.22% |
Net Income | -7.1M | ↓ 24.11% |
Net Profit Margin | -49.61% | ↑ 27.67% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 14.4M | ↑ 0.38% |
Net Income | -7.4M | ↑ 4.74% |
Net Profit Margin | -51.77% | ↓ 2.16% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 10.0M | ↓ 30.38% |
Net Income | -10.9M | ↑ 46.95% |
Net Profit Margin | -109.27% | ↓ 57.5% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 27.7M | - |
Total Liabilities | 77.9M | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 37.7M | ↑ 35.73% |
Total Liabilities | 100.8M | ↑ 29.4% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 178.8M | ↑ 374.82% |
Total Liabilities | 39.8M | ↓ 60.54% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 260.9M | ↑ 45.9% |
Total Liabilities | 46.3M | ↑ 16.38% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 242.6M | ↓ 7.02% |
Total Liabilities | 52.0M | ↑ 12.28% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 203.0M | ↓ 16.33% |
Total Liabilities | 37.5M | ↓ 27.89% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 242.6M | ↓ 2.69% |
Total Liabilities | 52.0M | ↓ 1.5% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 218.4M | ↓ 9.97% |
Total Liabilities | 37.8M | ↓ 27.3% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 210.8M | ↓ 3.47% |
Total Liabilities | 36.4M | ↓ 3.77% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 208.5M | ↓ 1.12% |
Total Liabilities | 38.5M | ↑ 5.98% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 203.0M | ↓ 2.64% |
Total Liabilities | 37.5M | ↓ 2.74% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 189.8M | ↓ 6.5% |
Total Liabilities | 32.9M | ↓ 12.25% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -8.9M | - |
Investing Cash Flow | -1.2M | - |
Financing Cash Flow | 4.0M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -11.0M | ↑ 23.67% |
Investing Cash Flow | -392.0K | ↓ 66.41% |
Financing Cash Flow | 22.2M | ↑ 456.9% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.1M | ↓ 137.54% |
Investing Cash Flow | -9.0K | ↓ 97.7% |
Financing Cash Flow | 137.2M | ↑ 516.95% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -29.1M | ↓ 803.99% |
Investing Cash Flow | -737.0K | ↑ 8088.89% |
Financing Cash Flow | 94.7M | ↓ 30.95% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -20.9M | ↓ 28.03% |
Investing Cash Flow | -15.8M | ↑ 2044.78% |
Financing Cash Flow | 1.2M | ↓ 98.76% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.1M | ↑ 3.6% |
Investing Cash Flow | -612.0K | ↓ 95.78% |
Financing Cash Flow | 411.0K | ↑ 140.35% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -10.6M | ↑ 108.11% |
Investing Cash Flow | -1.2M | ↑ 93.63% |
Financing Cash Flow | -15.4M | ↓ 3842.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -7.9M | ↓ 25.97% |
Investing Cash Flow | -19.9M | ↑ 1582.36% |
Financing Cash Flow | -401.0K | ↓ 97.39% |
Sell
Neutral
Buy
908 Devices Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() 908 Devices Inc. | 11.0% | -25.0% | -20.37% | -82.53% | -88.67% |
![]() Stryker Corporation | -3.84% | 5.16% | 12.86% | 24.25% | 52.69% |
![]() Boston Scientific Corp. | -3.68% | 21.48% | 41.72% | 68.89% | 76.47% |
![]() Edwards Lifesciences Corp. | -34.8% | -18.49% | -34.85% | -45.17% | -15.86% |
![]() Abbott Laboratories | 1.03% | -5.4% | -7.12% | -11.35% | 20.75% |
![]() Medtronic Plc | -1.99% | -9.34% | -13.21% | -38.74% | -23.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() 908 Devices Inc. | NA | NA | NA | -1.12 | -0.21 | -0.13 | NA | 4.76 |
![]() Stryker Corporation | 38.91 | 38.91 | 2.92 | 11.95 | 0.19 | 0.07 | 0.01 | 50.33 |
![]() Boston Scientific Corp. | 63.22 | 63.22 | 1.8 | 2.37 | 0.09 | 0.05 | NA | 13.16 |
![]() Edwards Lifesciences Corp. | 36.4 | 36.4 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 33.84 | 33.84 | 5.99 | 4.66 | 0.15 | 0.06 | 0.02 | 22.31 |
![]() Medtronic Plc | 28.97 | 28.97 | 1.52 | 5.2 | 0.07 | 0.04 | 0.04 | 38.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() 908 Devices Inc. | Buy | $189.3M | -88.67% | NA | -68.56% |
![]() Stryker Corporation | Buy | $129.7B | 52.69% | 38.91 | 16.03% |
![]() Boston Scientific Corp. | Buy | $114.3B | 76.47% | 63.22 | 12.05% |
![]() Edwards Lifesciences Corp. | Buy | $52.4B | -15.86% | 36.4 | 23.74% |
![]() Abbott Laboratories | Buy | $186.6B | 20.75% | 33.84 | 13.65% |
![]() Medtronic Plc | Buy | $102.5B | -23.49% | 28.97 | 11.36% |
Insights on 908 Devices Inc.
Revenue is down for the last 2 quarters, 14.35M → 9.99M (in $), with an average decrease of 30.4% per quarter
Netprofit is down for the last 3 quarters, -7.09M → -10.91M (in $), with an average decrease of 25.8% per quarter
In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 62.1%
In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 151.4%
ARK Investment Management LLC
Ameriprise Financial Inc
Vanguard Group Inc
Granahan Investment Management Inc..
BlackRock Inc
Eventide Asset Management, LLC
908 devices, is democratizing chemical analysis by way of mass spectrometry, offering point-of-need chemical analysis devices ranging from rugged, handheld chemical detection tools to compact, tiny footprint analyzers and fast separation devices. these purpose-built and user-centric devices serve a range of industries including safety and security, oil & gas, life sciences and other applied markets. 908 devices is headquartered in the heart of boston where they research, design and manufacture innovative products based on high pressure mass spectrometry (hpms).
Organization | 908 Devices Inc. |
Employees | 230 |
CEO | Dr. Kevin J. Knopp Ph.D. |
Industry | Technology |